

Ananase, Dayto Anase, Traumanase
An enzyme obtained from the stem of pineapple, bromelain belongs to a group of plant-derived proteolytic enzymes that also includes papain, and has a wide range of applications. In vitro and some in vivo studies demonstrate its anti-inflammtory (15) (16) properties. Bromelain reduces serum fibrinogen levels, supports fibrinolysis and has been investigated for its debriding effects on burn wounds (1). In addition, it may be useful for treating some skin conditions (2). Bromelain reduces mild, acute knee pain in a dose-dependent fashion (3). Studies of bromelain’s pain relieving effect on patients with arthritis yielded mix results (4) (5) (6).
Studies done in vitro and in mice have shown that bromelain has chemopreventive (19) (25) and antitumorigenic effects (20) (26). Bromelain and other proteolytic enzymes were used as adjuvants in cancer treatments (7) (8) (9). It also increased the survival indices of animals bearing leukemia, sarcoma, lung, breast, and ascetic tumors (10); however, the anticancer effects of bromelain have not been evaluated in clinical trials.
Theoretically, bromelain may interfere with anticoagulation therapy and increase bleeding risk due to its antithrombotic effects. Bromelain also inhibits cytochrome P450 (CYP) 2C9 activity (12).
Pineapple
Proteolytic removal of cell surface molecules by bromelain may account for some of its activities. Studies show that bromelain prevents platelet aggregation and adhesion of platelets to blood vessel endothelial cells as well as improves ischemia-reperfusion injury (13). It can act as an anti-inflammatory agent by reducing levels of prostaglandin E2 and thromboxane A2 (9). In addition, bromelain inhibits neutrophil migration in response to IL-8 during inflammation (14) and decreases pro-inflammatory chemokine and cytokine secretion (15) (16). Topical application of bromelain may be used for the skin debridement of burns (1).
Oral enzymes such as bromelain have been proposed as additive agents for cancer therapy (8). Proposed mechanisms include down-regulation of the immunosuppressive cytokine, TGF-beta (7), direct inhibition of tumor cell growth, modulation of immune cell function, modulation of cell adhesion molecules (CAMs), and the effects on platelet aggregation and thrombosis mentioned above (8) (9). Studies does in mice showed that bromelain induced apoptosis-related proteins along with inhibition of NF-kappaB-driven Cox-2 expression by blocking the MAPK and Akt/protein kinase B signaling in DMBA-TPA-induced skin tumors (20).
Bromelain also induces the expression of autophagy-related proteins, light chain 3 protein B II (LC3BII), and beclin-1 thereby facilitating apoptosis in mammary carcinoma cells (26).
Absorption
Orally administered bromelain is absorbed intact through the intestine. Because of its proteolytic activity, about 50% of bromelain is rapidly complexed with an antiproteinase, namely alpha-2-macroglobulin (AMG). Proteolytic activity is maintained within this protective molecule, but reduced. In a recent human study, plasma half-life was determined to be 6-9 hours. Orally administered bromelain is absorbed at a rate of 40% in animal studies.
Distribution
Bromelain is distributed in the blood and plasma.
Metabolism/Excretion
The pathways of metabolism and excretion are not fully known.
(11)
Klein G, et al. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006;24(1):25-30.
Phlogenzyme (PE), a combination therapy including bromelain (90 mg), trypsin (48 mg), and rutoside (100 mg), was compared with a standard non-steroidal anti-inflammatory drug (NSAID), diclofenac (DC; 50 mg), in this double-blind, randomized study of 90 osteoarthritis patients. Participants were either given PE (2 tablets t.i.d.) or DC (1 tablet b.i.d.) for 6 weeks, and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) dimensions and the Lequesne’s index were used to measure pain, joint stiffness, and physical function. Both PE and DC improved pain, joint stiffness, and physical function to similar levels, and patients receiving PE reported a small increase in drug tolerability. These results indicate that PE may be a useful alternative to NSAID therapy for osteoarthritis patients. Because PE is a combination therapy, the effects of bromelain alone were not determined.
Desser L, et al. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol 2001;47suppl:S10-S15.
The effect of a combination of oral proteolytic enzymes (OET) containing papain, bromelain, trysin and chymotrypsin on the levels of cytokin-transforming growth factor-beta (TGF-beta) was studied. Overproduction of TGF-beta is involved in chronic inflammation and delayed wound healing and is associated with adverse effects from chemo- and radiationtherapy. 52 patients with rheumatoid arthritis, osteomyelofibrosis or herpes zoster were recruited. 78 healthy volunteers served as controls. OET were shown to reduce TGF-beta1 only in patients with elevated TGF-beta1 concentration (> 50 ng/ml serum). This study was well designed and has a relatively high level of statistical significance. However, it included other OET in addition to bromelain, leaving the possibility that the outcome was due to a synergy of all the OET. The effect of bromelain alone was not identified.
Bottom Line: Bromelain is a digestive aid. It has not been shown to treat or prevent cancer or other serious medical conditions.
Bromelain, obtained from the stem of the pineapple, is an enzyme that breaks down protein molecules. In laboratory experiments, bromelain prevented several steps of blood clotting and decreased some substances that cause inflammation. Bromelain increases the absorption of antibiotics and when used topically, helps remove dead and damaged tissue from burns. Bromelain can help digestion and absorption in patients with digestive tract cancers. Anticancer activity has not been studied in humans.
Rheumatoid arthritis, osteomyelofibrosis or herpes zoster (shingles):
Bromelain was studied in combination with other proteases (papain, trypson, and chymotrypsin) in 78 healthy volunteers and 52 patients with rheumatoid arthritis, osteomyelofibrosis or herpes zoster. Before and after therapy, the researchers measured blood levels of TGF-beta, a substance involved in chronic inflammation, delayed wound healing, and side effects from chemo- and radiation therapy. The enzymes were found to reduce levels of TGF-beta, but only in the patients who had elevated TGF-beta blood levels to begin with. However, it is possible that this outcome was due to an additive effect of all four enzymes, and it is still unclear whether bromelain alone would have any effect.
In a clinical study that included 90 osteoarthritis patients, Phlogenzyme (PE), a therapy that contains bromelain as well as other components, was compared with a standard non-steroidal anti-inflammatory drug, diclofenac (DC). Participants were either given PE or DC for 6 weeks after which pain, joint stiffness, and physical function were measured. Both PE and DC improved pain, joint stiffness, and physical function similarly, and patients receiving PE reported a small increase in drug tolerability. Therefore, PE may be a useful alternative to taking NSAIDs for osteoarthritis; however, because PE is a combination therapy, the action of bromelain alone is not known.
Bromelain may increase blood levels of antibiotics by increasing their absorption in the intestine.